Press coverage about XOMA (NASDAQ:XOMA) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XOMA earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.1513956220619 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
XOMA (XOMA) traded up $0.44 during trading hours on Monday, reaching $33.71. The company’s stock had a trading volume of 96,400 shares, compared to its average volume of 170,222. The stock has a market cap of $274.54, a PE ratio of -10.34 and a beta of 3.17. XOMA has a 52 week low of $3.96 and a 52 week high of $37.25. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 3.53.
XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported $1.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $2.79. XOMA had a negative return on equity of 1.14% and a negative net margin of 3.51%. sell-side analysts forecast that XOMA will post -0.08 EPS for the current year.
In other XOMA news, CEO James R. Neal sold 46,296 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $28.24, for a total value of $1,307,399.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Thomas M. Burns sold 6,983 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $30.99, for a total value of $216,403.17. Following the completion of the sale, the chief financial officer now owns 13,538 shares in the company, valued at $419,542.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 87,069 shares of company stock valued at $2,517,993. Corporate insiders own 3.02% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “XOMA (XOMA) Receiving Somewhat Positive News Coverage, Report Finds” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/xoma-xoma-earning-somewhat-positive-news-coverage-report-shows/1817888.html.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.